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Benchmark Dose Modeling: A biomarker was 
deemed “sensitive” if the response to quartz (a 
highly toxic dust) was at least 10-fold higher than 
the response to TiO2 (low toxicity dust). In 
addition, the benchmark fit to the data had to meet 
acceptability criteria for the fit to the data. By 
comparing the BMDs from the dose-response 
curves of sensitive biomarkers, we estimated safe 
exposure levels for astronauts (example in Figure 
3). BMD comparisons were made to PELs that are 
known (Qz and TiO2) and to be estimated (lunar 
dusts A, C, and E) on a log-log plot. The numbers 
shown in red are the log BMD values for neutrophil 
counts 4 w after dust instillation.  
Results: The first step in this process was to 
establish a line on a log-log plot of the known 
permissible exposure levels (PELs) against the 
biomarker response, and then locate the 
responses to the lunar dusts on this line 
according to the response of each to the 
biomarker (Figure 3). Five biomarkers produced 
acceptable data at one or both time points (1 
week or 1 month after instillation). The results 
are shown in the Table. From the tabulated 
results we concluded that unground lunar dust 
and dust ground by two different methods were 
not toxicologically distinguishable. The safe 
exposure estimates were 1.3 ± 0.4 mg/m3 (jet-
milled dust), 1.0 ± 0.5 mg/m3 (ball-milled dust), 
and 0.9 ± 0.3 mg/m3 (unground, natural dust) as 
shown in the table. 
Discussion: The CBMDM approach has a 
number of advantages over conventional ways 
of estimating safe human exposure levels. The 
conventional way is to expose a test species to 
the material in question from this determine a 
no-observed-adverse-effect-level (NOAEL). 
This level is taken as the point of departure 
(POD), to which large and somewhat arbitrary 
uncertainty factors are applied. These factors 
might include ones for interspecies differences, 
intraspecices differences, exposure time 
differences, etc.).  
Our approach anchors the estimates for 
lunar dusts to the PELs of 2 dusts that have well-
established PELs based on extensive data, both 
in test species and in humans. There is a single 
common control (vehicle exposed) for all 5 
dusts, which makes comparisons more precise. 
The BMD analysis also uses all the data from 
the dose response profiles instead of just a 
single-point NOAEL. The profiles were 
generated using no more than 0.5g of lunar dust. 
Finally, multiple comparisons using a variety of 
toxicological endpoints, both biochemical and 
cellular can be used in forming the final 
estimates of safe human exposure levels. 
The safe exposure estimates should be 
applied just like PELs are applied to earth based 
workers. Astronauts’ exposures will be very 
similar to those workers. Depending on suit 
design, after each extravehicular activity (EVA) 
dust will enter the habitat and be scrubbed from 
the air over several hours. The plans are that 
EVAs will be conducted only during the work 
week and on weekends the astronauts will 
remain inside the habitat. This is parallel to 
industrial workers’ exposures and is the basis 
assumed for the setting of PELs.  
Conclusion: We estimate that 0.5 to 1 mg/m3 of 
lunar dust is safe for periodic human exposures 
during long stays in habitats on the lunar 
surface. This is not currently an official NASA 
standard.  
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Total white cells, 
1 w 
1.3 1.2 0.8 
Total white cells, 
4 w 
1.4 0.6 1.1 
Neutrophils, 1 w 0.5 0.9 0.5 
Macrophages, 1 w 1.4 1.2 1.2 
Macrophages, 4 w 1.7 0.6 2.3 
LDH, 1 w 1.3 1.2 0.9 
LDH, 4 w 2.0 0.7 1.0 
Macrophage 
stimulation, 1 w 
0.9 0.9 0.6 
Macrophage 
stimulation, 4 w 






0.9 ±0.3 1.0 
±0.5 
